This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The Catholic University of Korea. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Hye Mi Park: Innovator in Vaccine Development
Introduction
Hye Mi Park is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of immunology, particularly in vaccine development. Her innovative work has the potential to enhance the effectiveness of vaccines and improve patient outcomes.
Latest Patents
Hye Mi Park holds a patent for a CD4 T cell vaccine and its use. This invention relates to a CD4 T cell vaccine designed to increase intracellular viability and effectively induce an antigen-specific cytotoxic T lymphocyte (CTL) response. This advancement could play a crucial role in the development of more effective vaccines.
Career Highlights
Throughout her career, Hye Mi Park has been associated with notable institutions. She has worked with the Catholic University of Korea Industry-Academic Cooperation Foundation, where she contributed to various research initiatives. Additionally, she has been involved with Olipass Corporation, furthering her impact in the field of biotechnology.
Collaborations
Hye Mi Park has collaborated with esteemed colleagues, including Tai Gyu Kim and Hyun Il Cho. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Hye Mi Park is a trailblazer in the field of vaccine development, with her patent for a CD4 T cell vaccine showcasing her innovative spirit. Her work continues to inspire advancements in immunology and vaccine research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile